The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Acalabrutinib in patients with CLL and MCL undergoing alloSCT
Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland, comments on the administration of acalabrutinib after allogeneic stem cell transplantation (alloSCT) in patients with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). Prof. Jurczak also comments on how the rapid advances in CAR-T cell therapies may impact this. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
